Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07679581 · ClinicalTrials.gov registry record
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4
A clinical trial, sponsored by L. Cinnamon Bidwell.
- Recruiting
- Registry status
- 64
- Enrollment target
NCT07679581: Recruiting study, sponsored by L. Cinnamon Bidwell.
NCT07679581 is a clinical trial that is actively recruiting participants, run by L. Cinnamon Bidwell. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07679581 is actively recruiting participants, sponsored by L. Cinnamon Bidwell.
- RECRUITING
- Registry status
- 64 participants
- Enrollment target
Study Summary
This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Primary Outcome
The FN400 event-related potential (ERP) old/new effect will be measured using electroencephalography (EEG) during a recognition memory test. The FN400 reflects familiarity-based memory retrieval and is defined as the mean ERP amplitude difference between correctly recognized previously presented items ("hits") and correctly rejected novel items ("correct rejections") at mid-frontal electrode sites during the 300-500ms post-stimulus interval.
Interventions
- DRUG Cannabis (smoked flower)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2027-05-31 |
What NCT07679581 shows while recruiting
NCT07679581 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cannabis (smoked flower) is the first listed.
NCT07679581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07679581 about?
NCT07679581 is a clinical study titled "Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4". This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not in...
What is the current status of trial NCT07679581?
This trial is currently recruiting. The enrollment target is 64 participants. The study started on 2025-12-10. Estimated completion is 2027-05-31.
What interventions are being tested in trial NCT07679581?
The interventions under investigation include: Cannabis (smoked flower) (DRUG).
Who is sponsoring clinical trial NCT07679581?
This trial is sponsored by L. Cinnamon Bidwell, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI